Patients in the United States who meet the following criteria should be evaluated as a PUI for 2019-nCoV.
在美国, 符合以下条件者为2019-nCoV医学观察病例。
Clinical Features 临床表现 |
& |
Epidemiologic Risk 流行病学史 |
Fever1 or signs/symptoms of lower respiratory illness (e.g. cough or shortness of breath) 发热1或下呼吸道疾病的体征/症状(例如咳嗽或呼吸急促) |
AND 以及 |
Any person, including health care workers, who has had close contact2 with a laboratory-confirmed3,4 2019-nCoV patient within 14 days of symptom onset 在症状发作起14天内与经实验室确诊3,4的2019-nCoV患者密切接触2的任何人,包括医护人员 |
Fever1 and signs/symptoms of a lower respiratory illness (e.g., cough or shortness of breath) 发热1和下呼吸道疾病的体征/症状(例如咳嗽或呼吸急促) |
AND 以及 |
A history of travel from Hubei Province, China5within 14 days of symptom onset 症状发作起14天内有中国5湖北省的旅居史 |
Fever1 and signs/symptoms of a lower respiratory illness (e.g., cough or shortness of breath) requiring hospitalization4 发热1和需要住院的下呼吸道疾病的体征/症状(例如咳嗽或呼吸急促)4 |
AND 以及 |
A history of travel from mainland China5 within 14 days of symptom onset 症状发作起14天内有中国大陆的旅居史 |
The criteria are intended to serve as guidance for evaluation. Patients should be evaluated and discussed with public health departments on a case-by-case basis if their clinical presentation or exposure history is equivocal (e.g., uncertain travel or exposure).
本标准旨在用于筛查评估。若疑似病例的临床表现或流行病学史模棱两可(例如,不确定的出行或暴露情况),则应与公共卫生部门逐案进行评估和讨论。
(邓睿 编译)